Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Y. Kito; T. Yamada; T. Matsumoto; H. Yasui; K. Murata; A. Makiyama; H. Hara; E. Baba; K. Nishio; K. Yoshimura; S. Hironaka; K. Muro; K. Yamazaki

doi:10.1093/annonc/mdy281.151

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Y. Kito, T. Yamada, T. Matsumoto, H. Yasui, K. Murata, A. Makiyama, H. Hara, E. Baba, K. Nishio, K. Yoshimura, S. Hironaka, K. Muro, K. Yamazaki

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

本文言語	英語
ページ（範囲）	viii201
ジャーナル	Annals of oncology : official journal of the European Society for Medical Oncology
巻	29
DOI	https://doi.org/10.1093/annonc/mdy281.151
出版ステータス	出版済み - 10月 1 2018

!!!All Science Journal Classification (ASJC) codes

血液学
腫瘍学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1093/annonc/mdy281.151

他のファイルとリンク

引用スタイル

Kito, Y., Yamada, T., Matsumoto, T., Yasui, H., Murata, K., Makiyama, A., Hara, H., Baba, E., Nishio, K., Yoshimura, K., Hironaka, S., Muro, K., & Yamazaki, K. (2018). Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii201. https://doi.org/10.1093/annonc/mdy281.151

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. / Kito, Y.; Yamada, T.; Matsumoto, T. その他.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii201.

研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

Kito, Y, Yamada, T, Matsumoto, T, Yasui, H, Murata, K, Makiyama, A, Hara, H, Baba, E, Nishio, K, Yoshimura, K, Hironaka, S, Muro, K & Yamazaki, K 2018, 'Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii201. https://doi.org/10.1093/annonc/mdy281.151

Kito Y, Yamada T, Matsumoto T, Yasui H, Murata K, Makiyama A その他. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 10月 1;29:viii201. doi: 10.1093/annonc/mdy281.151

@article{6d553fc902ad44228e92944dec8d1674,

title = "Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G",

author = "Y. Kito and T. Yamada and T. Matsumoto and H. Yasui and K. Murata and A. Makiyama and H. Hara and E. Baba and K. Nishio and K. Yoshimura and S. Hironaka and K. Muro and K. Yamazaki",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy281.151",

language = "English",

volume = "29",

pages = "viii201",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC)

T2 - WJOG9216G

AU - Kito, Y.

AU - Yamada, T.

AU - Matsumoto, T.

AU - Yasui, H.

AU - Murata, K.

AU - Makiyama, A.

AU - Hara, H.

AU - Baba, E.

AU - Nishio, K.

AU - Yoshimura, K.

AU - Hironaka, S.

AU - Muro, K.

AU - Yamazaki, K.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530641&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy281.151

DO - 10.1093/annonc/mdy281.151

M3 - Article

C2 - 32136419

SN - 0923-7534

VL - 29

SP - viii201

JO - Annals of Oncology

JF - Annals of Oncology

ER -